Advanced glycation: A novel outlook on atherosclerosis

Current Pharmaceutical Design

Volumn 13, Issue 36, 2007, Pages 3681-3687

  Price, C L ^a   Knight, S C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Advanced glycation; Atherosclerosis; Immune cells; Methylglyoxal; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYSTEINE PROTEINASE; MATRIX METALLOPROTEINASE; METHYLGLYOXAL; REACTIVE OXYGEN METABOLITE;

ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL INFECTION; CHLAMYDOPHILA PNEUMONIAE; CYTOMEGALOVIRUS; DENDRITIC CELL; DIABETES MELLITUS; ENZYME ACTIVITY; HELICOBACTER PYLORI; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INSULIN RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ATHEROSCLEROSIS; BACTERIAL INFECTIONS; CYSTEINE ENDOPEPTIDASES; DENDRITIC CELLS; DIABETES COMPLICATIONS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MATRIX METALLOPROTEINASES; MITOCHONDRIA; PYRUVALDEHYDE; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 37449000946     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207783018608     Document Type: Review

References (75)

1. Maillard LC. Action des acides amines sur les sucres: Formation des melanoidines par voie methodique. Compt Rend Acad Sci 1912; 154: 66-8.
2. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67 (1): 3-21.
3. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44 (2): 129-46.
4. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 2003; 31 (Pt 6): 1358-63.
5. Thomalley PJ Dicarbonyl intermediates in the maillard reaction. Ann N Y Acad Sci 2005; 1043: 111-7.
6. Kalapos MP. Methylglyoxal in living organisms: chemistry, biochemistry, toxicology and biological implications. Toxicol Lett 1999; 110 (3): 145-75.
7. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci(Lond) 1994; 87 (1): 21-9.
8. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, et al, M. Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 2003; 44 (12): 5287-92.
9. Ahmed N, Thornalley PJ Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. Ann N Y Acad Sci 2005; 1043: 260-6.
10. Ahmed N, Thornalley PJ. Quantitative screening of protein bio-markers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 2003; 31 (Pt 6): 1417-22.
11. Ahmed N, Thornalley PJ. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 2002; 364 (Pt 1): 15-24.
12. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 2003; 31 (Pt 6): 1423-5.
13. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-7.
14. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375 (Pt 3): 581-92.
15. Schmidt AM, Yan S D, Yan SF, Stern D. M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-55.
16. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, et al. (epsilon)-carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-9.
17. Westwood ME, McLellan AC, Thornalley PJ Receptor-mediated endocytic uptake of methylglyoxal-modified serum albumin. Competition with advanced glycation end product-modified serum albumin at the advanced glycation end product receptor. J Biol Chem 1994; 269: 32293-8.
18. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
19. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-86.
20. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-808.
21. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 1998; 111-112: 137-51.
22. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 2000; 86: E50-4.
23. Xu B, Chibber R, Ruggiero D, Kohner E Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-91.
24. El Khoury J, Thomas CA, Loike JD, Hickman SE, Cao L, Silverstein SC. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994; 269: 10197-200.
25. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu F T, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-46.
26. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996; 93: 11047-52.
27. Horiuchi S, Unno Y, Usui H, Shikata K, Takaki K, Koito, et al. Padiological roles of advanced glycation end product receptors SR-A and CD36. Ann N Y Acad Sci 2005; 1043: 671-5.
28. Ohgami N, Miyazaki A, Sakai M, Kuniyasu A, Nakayama H, Horiuchi S. Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport: a new crossroad of AGE to cholesterol metabolism. J Atheroscler Thromb 2003; 10: 1-6.
29. Atherosclerosis. American Heart Association 2007; web pages http://www.americanheart,org/presenter.jhtml?identifier=4440.
30. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100.
31. Hennig B, Oesterling E, Toborek M. Environmental toxicity, nutrition, and gene interactions in the development of atherosclerosis. Nutr Metab Cardiovasc Dis 2007; 17: 162-9.
32. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg 2005; 19: 130-8.
33. Wautier JL. Schmidt AM Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004; 95: 233-8.
34. Drexler H. Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
35. Keller TT, Mairuhu AT, de Kruif MD, Klein SK, Gerdes VE, ten Cate, et al. Infections and endothelial cells. Cardiovasc Res 2003; 60: 40-8.
36. Al AlyZ. Edwards JC. Vascular biology in uremia: insights into novel mechanisms of vascular injury. Adv Chronic Kidney Dis 2004; 11: 310-8.
37. Turner E, Dishy V, Chung CP, Harris P, Pierces R, Asanuma Y, et al. Endothelial function in systemic lupus erythematosus: relationship to disease activity, cardiovascular risk factors, corticosteroid therapy, and coronary calcification, Vasc Health Risk Manag 2005; 1: 357-60.
38. Makin A J, Chung N A, Silverman SH, Moss MS, Lip GY. Indices of thrombogenesis, endothelial damage and platelet function following percutaneous peripheral artery angiography and angioplasty for peripheral vascular disease. Pathophysiol Haemost Thromb 2003; 33: 102-8.
39. Rojas A. Morales MA. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci 2004; 76: 715-30.
40. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res 2007; 100: 460-73.
41. Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW. Chemical modification of proteins during peroxidation of pbospholipids. J Lipid Res 2005; 46: 1440-9.
42. Frischmann M, Bidmon C, Angerer J, Pischetsrieder M. Identification of DNA adducts of methylglyoxal. Chem Res Toxicol 2005; 18: 1586-92.
43. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007; 99 (4A): 6B-14B.
44. Jia X, Olson DJ, Ross AR, Wu L. Structural and functional changes in human insulin induced by methylglyoxal. FASEB J 2006; 20: 1555-7.
45. Galis ZS, Khatri JJ Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.
46. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
47. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Nad Acad Sci USA 1995; 92: 402-6.
48. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
49. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006; 26: 380-92.
50. Garcia-Touchard A, Henry, TD, Sangiorgi G, Spagnoli LG, Mauriello A, Conover C, et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 2005; 25: 1119-27.
51. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-83.
52. Zeng J, Dunlop RA, Rodgers KJ, Davies MJ. Evidence for inactivation of cysteine proteases by reactive carbonyls via glycation of active site thiols. Biochem J 2006; 398: 197-206.
53. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007; 315 (5809): 201-5.
54. Tolbert BS, Tajc SC, Webb H, Snyder J, Nielsen JE, Miller BL, et al. The active site cysteine of ubiquitin-conjugating enzymes has a significantly elevated pKa: functional implications. Biochemistry 2005; 44: 16385-91.
55. Tiganis T, Bennett A. M. Protein tyrosine phosphatase function: the substrate perspective. Biochem J 2007; 402: 1-15.
56. Mussa FF, Chai H, Wang X, Yao Q, Lumsden AB, Chen C. Chlamydia pneumoniae and vascular disease: an update. J Vasc Surg 2006; 43: 1301-7.
57. Leinonen M, Saikku P. Infections and atherosclerosis. Scand Cardiovasc J 2000; 34: 12-20.
58. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998; 177: 725-9.
59. Ferguson GP, Totemeyer S, MacLean M J, Booth IR. Methylglyoxal production in bacteria: suicide or survival? Arch Microbiol 1998; 170: 209-18.
60. Booth IR, Ferguson GP, Miller S, Li C, Gunasekera B, Kinghorn S. Bacterial production of methylglyoxal: a survival strategy or death by misadventure? Biochem Soc Trans 2003; 31 (Pt 6): 1406-8.
61. Groyer E, Caligiuri G, Laschet-Khallou J, Nicoletti A. Immunological aspects of atherosclerosis. Presse Med 2006; 35 (3 Pt 2): 475-86.
62. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
63. Steinman, RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
64. Lipscomb MF, Masten BJ Dendritic cells: immune regulators in health and disease. Physiol Rev 2002; 82: 97-130.
65. Bobryshev YV, Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005; 26: 1700-4.
66. Perrin-Cocon L, Coutant F, Agaugue S, Deforges S, Andre P, Lotteau V. Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol 2001; 167: 3785-91.
67. Cho H, Shashkin P, Gleissner CA, Dunson DM, Jain N, Lee J, et al. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics 2007; 29: 149-60
68. Maroof A, English NR, Bedford PA, Gabrilovich DI, Knight SC. Developing dendritic cells become 'lacy' cells packed with fat and glycogen. Immunology 2005; 115: 473-83.
69. Price CL, Sharp PS, North ME, Rainbow SJ, Knight SC. Advanced glycation end products modulate the maturation and function of peripheral blood dendritic cells. Diabetes 2004; 53: 1452-8.
70. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176: 101-10.
71. Yilmaz A, Reiss C, Tantawi O, Weng A, Stumpf C, Raaz D, et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004; 172: 85-93.
72. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004; 101: 11779-84.
73. Marshall SM. The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 2007; 13(26): 2713-20.
74. Nilsson J, Nordin Fredrikson G, Schiopu A, Shah PK, Jansson B, Carlsson R. Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease. Curr Pharm Des 2007; 13(10): 1021-30.
75. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13(27): 2832-6.